Ad Ma Place
Ad Ma Place

Biological correlates associated with high-risk breast cancer patients identified using a computational method

almohamady7
AdMaPlace March 16, 2025
0 Comments

Introduction

Breast cancer is a highly heterogeneous disease, and encompasses multiple subtypes based on diverse molecular and histological backgrounds1,2,3. Although widely used for the classification of breast cancer, intrinsic subtypes are not significantly associated with prognosis and response to therapies4,5. A number of studies have been conducted to identify novel subgroups associated with poor prognosis outcomes in breast cancer using various genetic and genomic data6,7,8,9.

We previously developed aWCluster, a network-based method that integrates multi-omic data on a graph of cancer-related genes using optimal mass transport (OMT) to identify subgroups10. OMT provides a mathematical solution for assessing the similarity or distance between two samples by determining the optimal transportation mapping between mass distributions supported on a feature interaction network11. In the aWCluster study, mass distributions were constructed from integrated multi-omic data and the OMT approach was applied on a protein-protein interaction network. Hierarchical clustering was then applied to the resulting Wasserstein distance matrix to identify subgroups. The application of this unsupervised approach to multi-omic data, including gene expression, copy number alteration (CNA), and DNA methylation from The Cancer Genome Atlas Breast Invasive Carcinoma (TCGA-BRCA) dataset, identified a remarkably poor survival breast cancer group. Gene ontology analysis revealed that the subgroup was enriched in hypoxia-related biological pathways. aWCluster works by quantifying large-scale similarities among genes represented in a biological network using integrated multi-omic data. This finding provides a strong rationale to further analyze the resulting subgroup, which may possibly motivate altered clinical care.

Here, we investigate biological correlates of the poor prognosis breast cancer group, by analyzing mutational data, hypoxia signatures, immune cell abundance, leukocyte fraction, and spatial fraction of tumor-infiltrating lymphocytes (TILs) estimated on pathology images.

Results

Patients’ characteristics

Table 1 shows the evaluable cohort size in PAM50 subtypes and risk groups for each data type analyzed in the current study. Table 2 shows the clinical characteristics of the patients. Overall survival time was significantly lower in the high-risk group with a median 20.4 months compared to 28.8 months in the low-risk group (Wilcoxon rank-sum p = 0.0353). A higher rate of individuals (35.9% and 32.1%) in the high-risk group belonged to the luminal B and basal subtypes compared to those (18.0% and 16.2%) in the low-risk group (Fisher’s exact p = 7.7E−7). The ER status did not significantly differ between the high and low-risk groups (p = 0.3842). However, the low-risk group had a higher rate of PR-positive breast cancer (68.8%) compared to the high-risk group (53.1%) with p = 0.0267 and the high-risk group had a higher rate of HER2-positive breast cancer (28.6%) compared to the low-risk group (12.8%) with p = 0.0316. Additionally, the high-risk group was enriched for T2 (79.3%) and stage II tumors (69.2%) compared to the low-risk group (56.0% and 56.3% with p = 0.0008 and 0.0011, respectively). Basal subtype was enriched in African American individuals (37.4%), compared to Asian (8.1%) and White (12.9%) individuals with p = 5.6E−10. Furthermore, a higher rate of African American individuals belonged to the high-risk group (11.5%) than Asian (8.1%) and White (5.8%) individuals with p = 0.0527 (Supplementary Table 1).

Table 1 The evaluable cohort size for each data type including CIBERSORT score, somatic mutation, hypoxia signature, estimated spatial fraction of tumor-infiltrating lymphocytes, and leukocyte fraction data
Full size table
Table 2 Clinical characteristics. Statistical analysis was performed using Wilcoxon rank-sum test and Fisher’s exact test for continuous and categorical variables, respectively. Cases with X stage in T, N, and M or NA were excluded in the statistical analysis
Full size table

Differential mutation analysis

Somatic mutation data were available for 660 breast cancer cases from the TCGA, including 48 and 612 cases in the high and low-risk groups, respectively. Differential mutation analysis showed that PIK3CA and TP53 were the top two most frequently mutated genes in the entire cohort (each 34%; Fig. 1). Remarkably, the mutation rates for these two genes were significantly different between the high and low-risk groups; the low-risk group had a higher mutation rate (36.1%, 221/612 vs 10.4%, 5/48; Fisher’s exact p = 0.0002) in PIK3CA, whereas the high-risk group had a higher mutation rate (54.2%, 26/48 vs 32.2%, 197/612; p = 0.0038) in TP53. In addition, mutations in both PIK3CA and TP53 were found to be mutually exclusive with GATA3 as well as CDH1 mutations (McNemar p < 0.0001). The differential mutation analysis was also conducted, comparing mutation rates between the high and low-risk groups within each specific PAM50 subtype. We focused on the basal and luminal B subtypes given their high rates in the high-risk group, representing 33.3% (N = 16) and 39.6% (N = 19) of cases, respectively. In the luminal B subtype, mutations in PIK3CA were statistically significantly more frequent in the low-risk group (31.9%, 37/116) compared to the high-risk group (5.3%, 1/19; p = 0.0142; Supplementary Fig. 1). When the basal and luminal B subtypes were combined, the mutational rate difference in PIK3CA was marginally significant between the high (5.7%, 2/35) and low (18.7%, 40/214) risk groups (p = 0.0848). We also assessed differences in tumor mutational burden (TMB) and mutations of two DNA repair genes (BRCA1 and BRCA2) between the high and low-risk groups but found no significant differences.

Fig. 1: Oncoprint of the top ten most frequently mutated genes in the TCGA-BRCA.
figure 1

The three bars in the bottom indicate the breast cancer risk groups (high [N = 48] and low [N = 612]), survival status, and PAM50 subtypes, respectively.

Full size image

Survival analysis

As in the previous study10, the follow-up time was truncated at 5 years. In the current study, for the four breast cancer subgroups determined from the previous study, the distinctly poor survival group was denoted as the high-risk group and the other three subgroups were merged and denoted as the low-risk group. Kaplan-Meier survival analysis revealed a statistically significant difference in overall survival between the high (N = 53) and low-risk (N = 673) groups (log-rank p = 0.0006; Fig. 2). The PAM50-based subtype analysis showed marginal statistical significance (p = 0.0771) between the high and low-risk groups in the basal subtype, and a non-significant difference (p = 0.1720) in the luminal B subtype (Supplementary Fig. 2). However, when the basal and luminal B subtypes were combined, the survival rates between the high and low risk groups were significantly different with p = 0.0214 (Supplementary Fig. 2).

Fig. 2: Kaplan-Meier survival analysis between the high (N = 53) and low (N = 673) risk breast cancer groups.
figure 2

For the four breast cancer subgroups determined from the previous aWCluster analysis10, the distinctly poor survival group was denoted as the high risk group and the other three subgroups were merged and denoted as the low risk group. The overall survival rates were significantly different between the two groups (log-rank p = 0.0006).

Full size image

Comparison of hypoxia signature scores

Hypoxia scores were available for 723 breast cancer cases including 53 and 670 in the high and low risk groups, respectively. For all three hypoxia signatures, the high-risk group showed statistically significantly higher hypoxia scores compared to the low-risk group (Wilcoxon rank-sum p < 0.0001; Fig. 3). In PAM50-based subtype analysis, hypoxia scores differed significantly among the five subtypes, with the basal and HER2 subtypes exhibiting higher scores compared to other subtypes for all three hypoxia signatures (Kruskal–Wallis p < 0.0001; Fig. 4). However, no statistically significant difference in hypoxia scores was observed between the high and low-risk groups within each subtype. Notably, breast cancers from African American individuals exhibited significantly higher hypoxia scores (average scores: 0.4, 5.3, and -2.5 in hypoxia signatures from Buffa, Ragnum, and Winter, respectively) compared to other races (Buffa: -13.6, p = 1.7E−11; Ragnum: 0.8, p = 2.0E−4; Winter: -14.3, p = 9.9E−9).

Fig. 3: Hypoxia scores for the high and low risk groups.
figure 3

Comparison of hypoxia scores computed for three different hypoxia signatures (Buffa26, Ragnum27, and Winter28) between the high (N = 53) and low (N = 670) risk breast cancer groups.

Full size image
Fig. 4: Hypoxia scores for the PAM50-based subtypes.
figure 4

Comparison of hypoxia scores computed for three different hypoxia signatures (Buffa26, Ragnum27, and Winter28) among the PAM50-based subtypes.

Full size image

CIBERSORT analysis to compare immune cell abundance

CIBERSORT scores were available for all 726 breast cancer cases. CIBERSORT analysis showed a statistically significantly higher abundance of CD8 T cells (Wilcoxon rank-sum p = 0.0053), CD4 memory resting T cells (p = 0.0001), monocytes (p = 0.0336), and resting dendritic cells (p < 0.0001) in the low risk group compared to the high risk group (Fig. 5). M0 macrophages showed a statistically significant greater abundance in the high risk group compared to the low risk group (p < 0.0001). In PAM50-based subtype analysis, the basal subtype showed a statistically significantly higher abundance of CD4 memory resting T cells (p = 0.0021) and regulatory Tregs T cells (p = 0.0030) in the low risk group and M0 macrophages (p = 0.0491) in the high risk group. The luminal B subtype showed a statistically significant greater abundance of resting dendritic cells (p = 0.0048) in the low risk group. When the basal and luminal B subtypes were combined, four immune cell types, including CD4 memory resting T cells (p = 0.0008), regulatory Tregs T cells (p = 0.0098), M1 macrophages (p = 0.0104), and resting dendritic cells (p = 0.0011), showed a statistically significantly higher abundance in the low risk group and M0 macrophages (p = 0.0094) in the high risk group (Table 3 and Supplementary Fig. 3).

Fig. 5: Immune cell type abundance for the high and low risk groups.
figure 5

Immune cell type abundance showing statistically significant differences (p < 0.05) between the high (N = 53) and low (N = 673) risk breast cancer groups.

Full size image
Table 3 Immune cell types (with p-values) with statistically significant differences (p < 0.05) between the high (N = 53) and low (N = 673) risk breast cancer groups across the entire cohort and within each PAM50 subtype
Full size table

Analysis of leukocyte fraction and tumor-infiltrating lymphocytes

Leukocyte fraction data were available for 609 breast cancer cases, including 47 and 562 in the high and low-risk groups, respectively. The leukocyte fraction had statistical significance on the entire cohort (Wilcoxon rank-sum p = 1.3E−5) as well as PAM50 subtypes including the basal (p = 4.2E−7), luminal B (p = 0.0214), and combined basal and luminal B subtypes (p = 6.0E−8) with higher leukocyte fractions in the low-risk group.

The spatial fraction of TILs estimated on pathology images was available for 617 breast cancer cases including 48 and 569 in the high and low risk groups, respectively12. The spatial fraction of TILs was not significantly different between the high and low-risk groups in the entire cohort. In PAM50-based subtype analysis, a statistically significantly higher spatial fraction of TILs was found in the low-risk group compared to the high-risk group within the basal subtype (Wilcoxon rank-sum p = 0.0361). Figure 6 illustrates two representative micrographs with the basal subtype included in the current study. Figure 6A displays the case (TCGA-A7-A26I) in the high-risk group with an estimated spatial fraction of TILs of 0.1% and rare stromal TILs (<1%) by histopathologic examination whereas Fig. 6B displays the case (TCGA-E2-A1B6) in the low-risk group with an estimated spatial fraction of TILs of 20.0% and a high extent of stromal TILs (60%).

Fig. 6: Representative micrographs of basal breast cancer cases included in the current study.
figure 6

Images were obtained from https://cancer.digitalslidearchive.org/; A low-power and B high-power micrographs of the high risk group case (TCGA-A7-A26I) with an estimated spatial fraction of TILs of 0.1%, depicting rare TILs and (C) low power and (D) high power micrographs of the low-risk group case (TCGA-E2-A1B6) with an estimated spatial fraction of TILs of 20.0%, which depicts a high extent of TILs. The spatial fraction of TILs was obtained from the study conducted by Saltz et al.12.

Full size image

In the high risk group, CNA and DNA methylation data were correlated with the leukocyte fraction and spatial fraction of TILs. A number of genes on DNA methylation data were found to be highly correlated with the leukocyte fraction. Pathway analysis was conducted on the top ranked 100 genes, revealing allograft rejection as a significantly enriched pathway (false discovery rate [FDR] = 2.5E-7).

Discussion

In our previous study, we developed a network-based multi-omic data integration method called aWCluster applied to RNA-Seq, CNA, and DNA methylation data10. By applying this unsupervised approach to the TCGA-BRCA, we identified a high-risk group with distinct biology and found that hypoxia-related pathways are associated with poor prognosis, using downstream bioinformatics approaches on RNA-Seq data. In the current study, we further investigated the biological features relevant to the high-risk group identified in the previous work, by analyzing various biological data including somatic mutation, hypoxia signatures, immune cell abundance, leukocyte fraction, and spatial fraction of TILs estimated on pathology images.

PIK3CA and TP53 were found to be the two most frequently mutated genes in the TCGA-BRCA, as well as differentially mutated genes between the high and low-risk groups. PIK3CA is the most commonly mutated gene in breast cancer, occurring in up to 40% of ER+/HER2- breast tumors13. Mutations in PIK3CA may lead to the activation of proliferation and apoptosis14. TP53 mutations are also common in breast cancer with a much higher mutation rate in the basal-like subtype and its mutation is known to be associated with more aggressive tumor characteristics15,16,17,18. In our analysis, the low-risk group had a higher mutation rate (36.1% vs 10.4%; Fisher’s exact p = 0.0002) in PIK3CA whereas the high-risk group had a higher mutation rate (54.2% vs 32.2%; p = 0.0038) in TP53. In particular, for the luminal B subtype, PIK3CA showed a statistically significant difference between the high and low-risk groups with p = 0.0142. Mutations were observed to be unevenly distributed across PAM50 subtypes. For instance, PIK3CA (3.2%), CDH1 (0.8%), and GATA3 (0%) were less frequently mutated in the basal subtype. In PAM50-based subtype analysis, we more focused on the basal and luminal B subtypes because of their high rates in the high-risk group (in total, 72.9%). It is worth noting that previous studies have reported that basal-like and triple-negative tumors are associated with aggressive clinical behavior and poor outcomes19 and luminal B tumors have a relatively higher grade and lead to worse prognosis compared to luminal A tumors20,21.

Individuals in the high-risk group were enriched for the basal and luminal B subtypes with a higher rate of HER2-positive and a lower rate of PR-positive breast cancer compared to the low-risk group. Not surprisingly, the high-risk group exhibited a lower proportion of T1 and stage I tumors (7.6% and 0%) relative to the low-risk group (26.5% and 16.7%).

Kaplan-Meier analysis showed a statistically significant survival difference between the high and low-risk groups across the entire cohort, as well as when combining the basal and luminal B subtypes. Three published hypoxia signatures were assessed, resulting in all statistically significant differences with the high-risk group having higher scores, but no statistically significant difference was observed within each PAM50 subtype. Notably, hypoxia scores differed significantly among the PAM50 subtypes, with the basal and HER2 subtypes exhibiting higher scores compared to other subtypes. A recent study reported that the VEGF-hypoxia signature is highly enriched in the basal subtype compared to other subtypes, with higher expression in women of African ancestry compared to While women, and is likely to be associated with poor outcomes22. This is in line with our findings that showed that African American individuals had a higher rate of basal subtype breast cancer with significantly higher hypoxia scores compared to other races. Significant differences in various immune cell types and leukocyte fraction were observed between the high and low-risk groups on the entire cohort, as well as within the different PAM50 subtypes, suggesting differences in the tumor immune microenvironment. In addition, within the basal subtype we observed a statistically significant difference in the spatial fraction of TILs estimated on pathology images between the high and low-risk groups, with a higher spatial fraction of TILs in the low-risk group.

These findings indicate that breast cancers with poor prognosis are associated with differential mutation rates in key genes, as well as higher hypoxia levels and differences in the tumor immune microenvironment such as lower TIL infiltration. We plan to further investigate biological correlates associated with poor outcomes in the unfavorable breast cancer subtype with the ultimate aim of improving clinical decision-making including therapeutic choices.

Methods

Subgroups in breast cancer

In the current study, we analyzed the TCGA-BRCA (N = 726). Here, we denoted the distinctly poor survival breast cancer group identified in our previous study10 as the “high risk group” (N = 53, 7.3%); all others were denoted as the “low risk group” (N = 673, 92.7%). PAM50 subtype information was obtained from two published breast cancer studies23,24. Figure 7 illustrates the data analysis pipeline and biological data analyzed using bioinformatic and statistical analysis methods. Ethical review was not required because only publicly available data were analyzed.

Fig. 7: Data analysis pipeline and biological data.
figure 7

CNA copy number alteration, TILs tumor-infiltrating lymphocytes.

Full size image

Differential mutation

For differential mutation analysis, TCGA pan-cancer mutational profiles with somatic mutation information aggregated at the gene level were downloaded from the Genomic Data Commons (GDC) database (https://gdc.cancer.gov/about-data/publications/mc3-2017)25.

Hypoxia scores

Gene expression-based tumor-hypoxia signatures developed by Buffa et al.26, Ragnum et al.27, and Winter et al.28 were assessed. Hypoxia scores computed on RNA-Seq data from the TCGA-BRCA for the three published signatures were downloaded from the cBioPortal database (https://www.cbioportal.org)29.

Immune cell abundance

TCGA-BRCA CIBERSORT scores that quantify 22 immune cell types using a support vector regression-based deconvolution method were downloaded from the GDC database (https://gdc.cancer.gov/about-data/publications/panimmune)30.

Spatial fraction of tumor-infiltrating lymphocytes

To develop digital-pathology-based diagnostic and prognostic biomarkers, Saltz et al. introduced a deep learning “computational stain” approach on pathology images to estimate the spatial fraction of TILs12. Prior to the analysis, each whole-slide image was partitioned into patches. The spatial fraction of TILs was determined by dividing the number of TIL-positive patches by the total number of identified patches on the tissue sample. The estimated spatial fraction of TILs and leukocyte fraction data quantified using DNA methylation arrays were downloaded from the study by Saltz et al.12. The spatial fraction of TILs was denoted as the fraction of TIL-positive patches out of the total number of patches within the tissue.

Statistical analysis

For statistical analysis, differences in these biological data between the high and low risk groups were assessed using Wilcoxon rank-sum test and Fisher’s exact test for continuous and categorical variables, respectively. To investigate mutual exclusivity in mutations between gene pairs of interest, the McNemar test was employed. For survival analysis, Kaplan-Meier analysis with log-rank test was used.

Categories: Breast cancer, Cancer genomics
Tags: ,

Related Articles

Energy metabolism in health and diseases

Energy metabolism in health and diseases

Energy metabolism is indispensable for sustaining physiological functions in living organisms and assumes a pivotal role across physiological and pathological conditions. This review provides an extensive overview of advancements in energy metabolism research, elucidating critical pathways such as glycolysis, oxidative phosphorylation, fatty acid metabolism, and amino acid metabolism, along with their intricate regulatory mechanisms. The homeostatic balance of these processes is crucial; however, in pathological states such as neurodegenerative diseases, autoimmune disorders, and cancer, extensive metabolic reprogramming occurs, resulting in impaired glucose metabolism and mitochondrial dysfunction, which accelerate disease progression. Recent investigations into key regulatory pathways, including mechanistic target of rapamycin, sirtuins, and adenosine monophosphate-activated protein kinase, have considerably deepened our understanding of metabolic dysregulation and opened new avenues for therapeutic innovation. Emerging technologies, such as fluorescent probes, nano-biomaterials, and metabolomic analyses, promise substantial improvements in diagnostic precision. This review critically examines recent advancements and ongoing challenges in metabolism research, emphasizing its potential for precision diagnostics and personalized therapeutic interventions. Future studies should prioritize unraveling the regulatory mechanisms of energy metabolism and the dynamics of intercellular energy interactions. Integrating cutting-edge gene-editing technologies and multi-omics approaches, the development of multi-target pharmaceuticals in synergy with existing therapies such as immunotherapy and dietary interventions could enhance therapeutic efficacy. Personalized metabolic analysis is indispensable for crafting tailored treatment protocols, ultimately providing more accurate medical solutions for patients. This review aims to deepen the understanding and improve the application of energy metabolism to drive innovative diagnostic and therapeutic strategies.

almohamady7
AdMaPlace March 19, 2025
0 Comments
Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets

Tissue macrophages: origin, heterogenity, biological functions, diseases and therapeutic targets

Macrophages are immune cells belonging to the mononuclear phagocyte system. They play crucial roles in immune defense, surveillance, and homeostasis. This review systematically discusses the types of hematopoietic progenitors that give rise to macrophages, including primitive hematopoietic progenitors, erythro-myeloid progenitors, and hematopoietic stem cells. These progenitors have distinct genetic backgrounds and developmental processes. Accordingly, macrophages exhibit complex and diverse functions in the body, including phagocytosis and clearance of cellular debris, antigen presentation, and immune response, regulation of inflammation and cytokine production, tissue remodeling and repair, and multi-level regulatory signaling pathways/crosstalk involved in homeostasis and physiology. Besides, tumor-associated macrophages are a key component of the TME, exhibiting both anti-tumor and pro-tumor properties. Furthermore, the functional status of macrophages is closely linked to the development of various diseases, including cancer, autoimmune disorders, cardiovascular disease, neurodegenerative diseases, metabolic conditions, and trauma. Targeting macrophages has emerged as a promising therapeutic strategy in these contexts. Clinical trials of macrophage-based targeted drugs, macrophage-based immunotherapies, and nanoparticle-based therapy were comprehensively summarized. Potential challenges and future directions in targeting macrophages have also been discussed. Overall, our review highlights the significance of this versatile immune cell in human health and disease, which is expected to inform future research and clinical practice.

almohamady7
AdMaPlace March 19, 2025
0 Comments
Breast cancer: pathogenesis and treatments

Breast cancer: pathogenesis and treatments

Breast cancer, characterized by unique epidemiological patterns and significant heterogeneity, remains one of the leading causes of malignancy-related deaths in women. The increasingly nuanced molecular subtypes of breast cancer have enhanced the comprehension and precision treatment of this disease. The mechanisms of tumorigenesis and progression of breast cancer have been central to scientific research, with investigations spanning various perspectives such as tumor stemness, intra-tumoral microbiota, and circadian rhythms. Technological advancements, particularly those integrated with artificial intelligence, have significantly improved the accuracy of breast cancer detection and diagnosis. The emergence of novel therapeutic concepts and drugs represents a paradigm shift towards personalized medicine. Evidence suggests that optimal diagnosis and treatment models tailored to individual patient risk and expected subtypes are crucial, supporting the era of precision oncology for breast cancer. Despite the rapid advancements in oncology and the increasing emphasis on the clinical precision treatment of breast cancer, a comprehensive update and summary of the panoramic knowledge related to this disease are needed. In this review, we provide a thorough overview of the global status of breast cancer, including its epidemiology, risk factors, pathophysiology, and molecular subtyping. Additionally, we elaborate on the latest research into mechanisms contributing to breast cancer progression, emerging treatment strategies, and long-term patient management. This review offers valuable insights into the latest advancements in Breast Cancer Research, thereby facilitating future progress in both basic research and clinical application.

almohamady7
AdMaPlace March 19, 2025
0 Comments
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines

The successful approval of peptide-based drugs can be attributed to a collaborative effort across multiple disciplines. The integration of novel drug design and synthesis techniques, display library technology, delivery systems, bioengineering advancements, and artificial intelligence have significantly expedited the development of groundbreaking peptide-based drugs, effectively addressing the obstacles associated with their character, such as the rapid clearance and degradation, necessitating subcutaneous injection leading to increasing patient discomfort, and ultimately advancing translational research efforts. Peptides are presently employed in the management and diagnosis of a diverse array of medical conditions, such as diabetes mellitus, weight loss, oncology, and rare diseases, and are additionally garnering interest in facilitating targeted drug delivery platforms and the advancement of peptide-based vaccines. This paper provides an overview of the present market and clinical trial progress of peptide-based therapeutics, delivery platforms, and vaccines. It examines the key areas of research in peptide-based drug development through a literature analysis and emphasizes the structural modification principles of peptide-based drugs, as well as the recent advancements in screening, design, and delivery technologies. The accelerated advancement in the development of novel peptide-based therapeutics, including peptide-drug complexes, new peptide-based vaccines, and innovative peptide-based diagnostic reagents, has the potential to promote the era of precise customization of disease therapeutic schedule.

almohamady7
AdMaPlace March 19, 2025
0 Comments

Integrated proteogenomic characterization of ampullary adenocarcinoma

Ampullary adenocarcinoma (AMPAC) is a rare and heterogeneous malignancy. Here we performed a comprehensive proteogenomic analysis of 198 samples from Chinese AMPAC patients and duodenum patients. Genomic data illustrate that 4q loss causes fatty acid accumulation and cell proliferation. Proteomic analysis has revealed three distinct clusters (C-FAM, C-AD, C-CC), among which the most aggressive cluster, C-AD, is associated with the poorest prognosis and is characterized by focal adhesion. Immune clustering identifies three immune clusters and reveals that immune cluster M1 (macrophage infiltration cluster) and M3 (DC cell infiltration cluster), which exhibit a higher immune score compared to cluster M2 (CD4+ T-cell infiltration cluster), are associated with a poor prognosis due to the potential secretion of IL-6 by tumor cells and its consequential influence. This study provides a comprehensive proteogenomic analysis for seeking for better understanding and potential treatment of AMPAC.

almohamady7
AdMaPlace March 9, 2025
0 Comments

Responses

Your email address will not be published. Required fields are marked *